Abstract
Introduction
The use of 2 × 2000 mg myo-inositol +2 × 200 μg folic acid per day is a safe and promising tool in the effective improvement of symptoms and infertility for patients with polycystic ovary syndrome (PCOS). In addition, PCOS is one of the pathological factors involved in the failure of in vitro fertilization (IVF). Typically, PCOS patients suffer of poor quality oocytes.
Patients and methods
In an open, prospective, non-blinded, non-comparative observational study, 3602 infertile women used myo-inositol and folic acid between 2 and 3 months in a dosage of 2 × 2000 mg myo-inositol +2 × 200 μg folic acid per day. In a subgroup of 32 patients, hormonal values for testosterone, free testosterone and progesterone were analyzed before and after 12 weeks of treatment. The mean time of use was 10.2 weeks. In the second part of this trial it was investigated if the combination of myo-inositol + folic acid was able to improve the oocyte quality, the ratio between follicles and retrieved oocytes, the fertilization rate and the embryo quality in PCOS patients undergoing IVF treatments. Twenty-nine patients with PCOS, underwent IVF protocols for infertility treatment and were randomized prospectively into two groups. Group A (placebo) with 15 patients and group B (4000 mg myo-inositol +400 μg folic acid per day) with 14 patients were evaluated. The patients of group B used 2 months’ myo-inositol + folic acid before starting the IVF protocol. For statistically analyses Student’s t-test was performed.
Results
Seventy percent of the women had a restored ovulation, and 545 pregnancies were observed. This means a pregnancy rate of 15.1% of all the myo-inositol and folic acid users. In 19 cases a concomitant medication with clomiphene or dexamethasone was used. One twin pregnancy was documented. Testosterone levels changed from 96.6 ng/mL to 43.3 ng/mL and progesterone from 2.1 ng/mL to 12.3 ng/mL in the mean after 12 weeks of treatment (p < 0.05) Student’s t-test. No relevant side effects were present among the patients. The women in the IVF treatment the group A showed a higher number of retrieved oocytes than group B. Nevertheless, the ratio follicle/retrieved oocyte was clearly better in the myo-inositol group (= group B). Out of the 233 oocytes collected in the myo-inositol group, 136 where fertilized whereas only 128 out of 300 oocytes were fertilized in the placebo group. With regards to the oocytes quality, better data were obtained in the myo-inositol group. More metaphase II and I oocytes were retrieved in relation to the total number of oocytes, when compared with the placebo group. Also, more embryos of grade I quality were observed in the myo-inositol group than in the placebo group. The duration of stimulation was 9.7 days (±3.3) in the myo-inositol group and 11.2 (±1.8) days in the placebo group and the number of used follicle-stimulating hormone (FSH) units was lower in the myo-inositol group in comparison to the placebo group: 1850 FSH units (mean) versus 1850 units (mean).
Discussion
Myo-inositol has proven to be a new treatment option for patients with PCOS and infertility. The achieved pregnancy rates are at least in an equivalent or even superior range than those reported using metformin as an insulin sensitizer. No moderate to severe side effects were observed when myo-inositol was used at a dosage of 4000 mg per day. In addition, our evidence suggests that a myo-inositol therapy in women with PCOS results in better fertilization rates and a clear trend to a better embryo quality. As by the same way the number of retrieved oocytes was smaller in the myo-inositol group, the risk of a hyperstimulation syndrome in these patients can be reduced. Therefore, myo-inositol also represents an improvement in IVF protocols for patients with PCOS.
Author Statement
Research funding: The authors report no funding.
Conflict of interest: Pedro-Antonio Regidor is Medical Director for Western European and Germany of Exeltis, a member of the INSUD Group, which distributes myo-inositol in Germany. Bernd Lesoine, Adolf Eduard Schindler and Rene Druckman declare no conflict of interest.
Informed consent: Informed consent was obtained from all participants.
Ethical approval: The research related to human use complied with all the relevant national regulations and institutional policies and was performed in accordance to the tenets of the Declaration of Helsinki and has been approved by the author’s institutional review board or equivalent committee.
References
[1] Ehrmann DA. Polycystic ovary syndrome. N Engl J Med. 2005;352:1223–36.10.1056/NEJMra041536Search in Google Scholar PubMed
[2] Homburg R. Polycystic ovary syndrome – from gynecological curiosity to multisystem endocrinopathy. Hum Reprod. 1996;11:29–39.10.1093/oxfordjournals.humrep.a019031Search in Google Scholar
[3] The Rotterdam ESHRE/ASRM‐sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19:41–7.10.1093/humrep/deh098Search in Google Scholar PubMed
[4] Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycstic ovary syndrome. Fertil Steril. 2004;81:19–25.10.1016/j.fertnstert.2003.10.004Search in Google Scholar
[5] Ehrmann DA, Barnes RB, Rosenfield RL, Cavaghan MK, Imperial J. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care. 1999;22:141–6.10.2337/diacare.22.1.141Search in Google Scholar PubMed
[6] Genazzani AD, Battaglia C, Malavasi B, Strucchi C, Tortolani F, Gamba O. Metformin administration modulates and restores luteinizing hormone spontaneous episodic secretion and ovarian function in nonobese patients with polycystic ovary syndrome. Fertil Steril. 2004;81:114–9.10.1016/j.fertnstert.2003.05.020Search in Google Scholar PubMed
[7] Ciampelli M, Fulghesu AM, Cucinelli F, Pavone V, Ronsisvalle E, Guido M, et al. Impact on insulin and body mass index on metabolic and endocrine variables in polycystic ovary syndrome. Metab Clin Exp. 1999;48:167–72.10.1016/S0026-0495(99)90028-8Search in Google Scholar
[8] Genazzani AD, Lanzone C, Ricchieri F, Jasonni M. Myo-inositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patientis with polycystic ovary syndrome. Gynecol Endocrinol. 2008;24:139–44.10.1080/09513590801893232Search in Google Scholar PubMed
[9] Croze ML, Soulage CO. Potential role and therapeutic interests of myo-inositol in metabolic diseases. Biochimie. 2013;95:1811–27.10.1016/j.biochi.2013.05.011Search in Google Scholar PubMed
[10] Baillargeon JP, Iuorno MJ, Nestler JE. Insulin sensitizers for polycystic ovary syndrome. Clin Obstet Gynecol. 2003;46:325–40.10.1097/00003081-200306000-00011Search in Google Scholar PubMed
[11] Strugaru AM, Botnariu G, Agoroaei L, Grigoriu IC, Butnaru E. Metformin induced lactic acidosis – particularities and course. Rev Med Chir Soc Med Nat Iasi. 2013;117:1035–42.Search in Google Scholar PubMed
[12] Kim C-H, Han K-A, Oh H-J, Tan KE, Sothiratnam R, Tjokroprawiro A, et al. Safety, tolerability, and efficacy of metformin extended-release oral antidiabetic therapy in patients with type 2 diabetes: an observational trial in Asia. J Diabetes. 2012;4:395–406.10.1111/j.1753-0407.2012.00220.xSearch in Google Scholar PubMed
[13] Clements R, Darnell B. Myo-inositol content of common foods: development of a high-myo-inositol diet. Am J Clin Nutr. 1980;33:1954–67.10.1093/ajcn/33.9.1954Search in Google Scholar PubMed
[14] Reynolds JE. Martindale-the Extra Pharmacopoeia, 30th ed. Pennsylvania: Rittenhouse Book Distributors; 1993. 1379 p. An isomer of glucose that has traditionally been considered to be a B vitamin although it has an uncertain status as a vitamin and a deficiency syndrome has not been identified in man.Search in Google Scholar
[15] Baillargeon JP, Nestler JE, Ostlund RE, Apridonidze T, Diamanti-Kandarakis E. Greek hyperinsulinemic women, with or without polycystic ovary syndrome, display altered inositol metabolism. Hum Reprod. 2008;24:139–44.10.1093/humrep/den097Search in Google Scholar PubMed PubMed Central
[16] Hooper NM. Glycosyl-phosphatidylinositol anchored membrane enzymes. Clin Chim Acta. 1997;266:3–12.10.1016/S0009-8981(97)00161-7Search in Google Scholar PubMed
[17] Kennington AS, Hill CR, Craig J, Bogardus C, Raz I, Ortmeyer HK, et al. Low urinary chiro-inositol excretion in non-insulin-dependent diabetes mellitus. N Engl J Med. 1990;323:373–8.10.1056/NEJM199008093230603Search in Google Scholar PubMed
[18] Asplin I, Galasko G, Larner J. Chiro-inositol-deficiency and insulin resistance: a comparison of the chiro-inositol- and myo-inositol containing insulin mediators isolated from urine, hemodialysate and muscle of control and type II diabetic subjects. Proc Natl Acad Sci USA. 1993;90:5924–8.10.1073/pnas.90.13.5924Search in Google Scholar PubMed PubMed Central
[19] Cohen P. The twentieth century struggle to decipher insulin signalling. Nat Rev Mol Cell Biol. 2006;7:867–73.10.1038/nrm2043Search in Google Scholar PubMed
[20] Baillargeon JP, Diamanti-Kandarakis E, Ostlund RE, Apridonidze T, Diamanti-Kandarakis E. Greek hyperinsulinemic woman, with or without polycystic ovary syndrome, display altered inositols metabolism. Hum Rep. 2008;23:1439–46.10.1093/humrep/den097Search in Google Scholar
[21] Baillargeon JP, Diamanti-Kandarakis E, Ostlund Jr RE, Apridonize T, Iuorno MT, Nestler JE. Altered D-chiro-inositol urinary clearance in women with polycystic ovary syndrome. Diabetes Care. 2006;29:300–5.10.2337/diacare.29.02.06.dc05-1070Search in Google Scholar PubMed
[22] Papaleo E, Unfer V, Baillargeon JP, De Santis L, Fusi F, Brigante C, et al. Myo-inositol in patients with polycystic ovary syndrome: a novel method for ovulation induction. Gynecol Endocrinol. 2007;23:700–3.10.1080/09513590701672405Search in Google Scholar PubMed
[23] Serhal PF, Ranieri DM, Kinis A, Marchant S, Davies M, Khadum IM. Oocyte morphology predicts outcome of intracytoplasmatic sperm injection. Hum Rep. 1997;12:1267–70.10.1093/humrep/12.6.1267Search in Google Scholar PubMed
[24] Macklon NS, Frauser BC. Mild stimulation in in vitro fertilization. Ann N Y Acad Sci. 2003;997:105–11.10.1196/annals.1290.012Search in Google Scholar PubMed
[25] Chiu TT, Rogers MS, Law EL, Briton-Jones CM, Cheung LP, Haines CJ. Follicular fluid and serum concentrations of myo-Inositol in patients undergoing IVF: relationship with oocyte quality. Hum Rep. 2002;17:1591–6.10.1093/humrep/17.6.1591Search in Google Scholar PubMed
[26] Chiu TT, Rogers MS, Briton-Jones C, Haines C. Effects of myo-Inositol on the in-vitro maturation and subsequent development of mouse oocytes. Hum Rep. 2003;18:408–4.10.1093/humrep/deg113Search in Google Scholar PubMed
[27] Nestler JE, Unfer V. Reflections on inositol(s) for PCOS therapy: steps toward success. Gynecol Endocrin. 2015;31:501–5.10.3109/09513590.2015.1054802Search in Google Scholar PubMed
[28] Carlomagno G, Unfer V, Roseff S. The D-chiroinositol paradox in the ovary. Fertil Steril. 2011;95:2515–6.10.1016/j.fertnstert.2011.05.027Search in Google Scholar PubMed
[29] Facchinetti F, Bizzarri M, Benvenga S, D’Anna R, Lanzone A, Soulage C, et al. Results from the International Consensus Conference on Myo-inositol and D-chiro-inositol in Obstetrics and Gynecology: the link between metabolic syndrome and PCOS. Eur J Obstet Gynecol Reprod Biol. 2015;195:72–6.10.1016/j.ejogrb.2015.09.024Search in Google Scholar PubMed
[30] Rizzo P, Raffone E, Benedetto V. Effect of the treatment with myo-inositol plus folic acid plus melatonin in comparison with a treatment with myo-inositol plus folic acid on oocyte quality and pregnancy outcome in IVF cycles. A prospective, clinical trial. Eur Rev Med Pharmacol Sci. 2010;14:555–61.Search in Google Scholar PubMed
[31] Unfer V, Raffone E, Rizzo P, Buffo S. Effect of a supplementation with myo-inositol plus melatonin on oocyte quality in women who failed to conceive in previous in vitro fertilization cycles for poor oocyte quality: a prospective, longitudinal, cohort study. Gynecol Endocrin. 2011;27:857–61.10.3109/09513590.2011.564687Search in Google Scholar PubMed
[32] Carlomagno G, Unfer V. Inositol safety: clinical evidences. Eur Rev Med Pharmacol Sci. 2011;15:931–6.Search in Google Scholar PubMed
[33] Iuorno MJ, Jakubowicz DJ, Baillargeon JP, Dillon P, Gunn RD, Allan G, et al. Effect of D-chiro-inositol in lean women with the polycystic ovary syndrome. Endocr Pract. 2002;8:417–23.10.4158/EP.8.6.417Search in Google Scholar PubMed
[34] Nestler JE, Jakubowicz DJ, Reamer P, Gunn RD, Allan G. Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome. N Engl J Med. 1999;340:1314–20.10.1056/NEJM199904293401703Search in Google Scholar PubMed
[35] Gerli S, Papaleo E, Ferrari A, Di Renzo GC. Effects of inositol on ovarian function and metabolic factors in women with PCOS: a randomized double blind placebo-controlled trial. Eur Rev Med Pharmacol Sci. 2003;7:151–9.Search in Google Scholar PubMed
[36] Unfer V, Carlomagno G, Dante G, Facchinetti F. Effects of myo-Inositol in women with PCOS: a systematic review of randomized controlled trials. Gynecol Endocrin. 2012;28:509–15.10.3109/09513590.2011.650660Search in Google Scholar
[37] Karimzadeh MA, Javedani M. An assessment of lifestyle modification versus medical treatment with clomiphene citrate, metformin, and clomiphene citrate-metformin in patients with polycystic ovary syndrome. Fertil Steril. 2010;94:216–20.10.1016/j.fertnstert.2009.02.078Search in Google Scholar PubMed
[38] Legro RS, Zaino RJ, Demers LM, Kunselman AR, Gnatuk CL, Williams NI, et al. The effects of metformin and rosiglitazone, alone and in combination, on the ovary and endometrium in polycystic ovary syndrome. Am J Obstet Gynecol. 2007;196:402.10.1016/j.ajog.2006.12.025Search in Google Scholar PubMed
[39] Gerli S, Papaleo E, Ferrari A, Di Renzo GC. Randomized, double blind placebo-controlled trial: effects of Myo-inositol on ovarian function and metabolic factors in women with PCOS. Eur Rev Med Pharmacol Sci. 2007;11:347–54.Search in Google Scholar PubMed
[40] Raffone E, Rizzo P, Benedetto V. Insulin sensitizer agents alone and in co-treatment with r-FSH for ovulation induction in PCOS women. Gynecol Endocrinol. 2010;26:275–80.10.3109/09513590903366996Search in Google Scholar
[41] Genazzani, AD, Prati A, Santagni S, Ricchieri F, Chierchia E, Rattighieri E, et al. Differential insulin response to myo-inositol administration in obese polycystic ovary syndrome patients. Gynecol Endocrinol. 2012;28:969–73.10.3109/09513590.2012.685205Search in Google Scholar PubMed
[42] Morgante G, Orvieto R, Di Sabatino A, Musacchio MC, De Leo V. The role of inositol supplementation in patients with polycystic ovary syndrome, with insulin resistance, undergoing the low-dose gonadotropin ovulation induction regimen. Fertil Steril. 2011;95:2642–4.10.1016/j.fertnstert.2011.01.035Search in Google Scholar PubMed
[43] Sun TH, Heimark DB, Nguygen T, Nadler JL, Larner J. Both myo-inositol to chiro-inositol epimerase activities and chiro-inositol to myo-inositol ratios are decreased in tissues of GK type 2 diabetic rats compared to Wistar controls. Biochem Biophys Res Commun. 2002;293:1092–8.10.1016/S0006-291X(02)00313-3Search in Google Scholar PubMed
[44] Battaglia C, Mancini F, Persico N, Zaccaria V, de Aloysio D. Ultrasound evaluation of PCO, PCOS and OHSS. Reprod Biomed Online. 2004;9:614–9.10.1016/S1472-6483(10)61770-1Search in Google Scholar PubMed
[45] Papaleo E, Unfer V, Baillargeon JP, Fusi F, Occhi F, De Santis L. Myo-inositol may improve oocyte quality in intracytoplasmatic sperm injection cycles. A prospectice, controlled, randomized trial. Fertil Steril 2009;91:1750–4.10.1016/j.fertnstert.2008.01.088Search in Google Scholar PubMed
[46] Constantino D, Minozzi G, Minozzi F, Guaraldi C. Matabolic and hormonal effects of myo-inositol in women with polycystic ovary syndrome: a double-blind trial. Eur Rev Med Pharmacol Sci. 2009;13:105–10.Search in Google Scholar
©2018 Walter de Gruyter GmbH, Berlin/Boston
